FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011648469> ?p ?o ?g. }

• W2011648469 endingPage "677" @default.
• W2011648469 startingPage "676" @default.
• W2011648469 abstract "In this issue of CHEST (see page 891), Carlos and Gustavo Rodrigo review studies that examine the clinical efficacy of heliox for the management of patients with asthma. To summarize, their meta-analysis concludes that the available data do not warrant the use of heliox for the treatment of most acute exacerbations of asthma. Heliox is a mixture of oxygen and helium that has a lower density and a higher viscosity than nitrogen-oxygen mixtures.1Manthous CA Morgan S Pohlman A et al.Heliox in the treatment of airflow obstruction: a critical review of the literature.Respir Care. 1997; 42: 1034-1042Google Scholar These physical properties reduce the Reynolds number associated with its flow through hollow tubes (ie, the airways). Heliox should, therefore, promote the transformation of some areas of turbulent flow, as is thought to occur in the bronchioles of asthmatic patients, to laminar flow, thereby reducing the resistive-pressure work of breathing. Dynamic hyperinflation also contributes to increased elastic pressure work of breathing in patients with acute asthma. By promoting enhanced expiratory flow, heliox also should reduce the elastic-pressure work of breathing by allowing the passive exhalation to a lower end-expiratory volume. If this theory is applicable, heliox does not treat asthma. It merely reduces the inspiratory pressures that the patient (or a ventilator) is required to generate during tidal breathing at any given flow and tidal volume. So, heliox may temporize and give definitive treatments (bronchodilators and steroids) time to work. It also could improve the efficacy of definitive therapies if it better carried aerosolized medications to the target airways. So, heliox may impact outcomes in one of the following two ways: by reducing the work of breathing sufficiently to preclude the need for endotracheal intubation (and/or to reduce the sense of dyspnea in those with severe airflow obstruction); and as a carrier gas to improve the delivery of aerosols to the airways, thereby improving disposition outcomes. To my knowledge, the successful clinical use of heliox was first published in anecdotal reports in the 1930s for the treatment of patients with severe asthma and upper airway obstruction.2Barach AL Use of helium as a new therapeutic gas.Proc Soc Exp Biol Med. 1934; 32: 462-464Crossref Scopus (74) Google Scholar3Barach AL The use of helium in the treatment of asthma and obstructive lesions of the larynx and trachea.Ann Intern Med. 1935; 9: 739-765Crossref Google Scholar4Barach AL The use of helium as a new therapeutic gas.Anesth Analg. 1935; 14: 210-215Crossref Scopus (30) Google Scholar Between the 1930s and the 1990s, there are few published accounts of heliox use for status asthmaticus.1Manthous CA Morgan S Pohlman A et al.Heliox in the treatment of airflow obstruction: a critical review of the literature.Respir Care. 1997; 42: 1034-1042Google Scholar Since 1990, numerous investigators have examined the utility of heliox for acute airflow obstruction, leading to the current meta-analysis showing no outcome benefits of this intervention. Nonetheless, the review points out that heliox can improve some physiologic variables (ie, peak flow and pulsus paradoxus) of patients with status asthmaticus.5Manthous CA Hall JB Caputo MA et al.The effect of heliox on pulsus paradoxus and peak flows in patients with severe asthma.Am J Respir Crit Care Med. 1995; 151: 310-314Crossref PubMed Scopus (170) Google Scholar6Kudukis TM Manthous CA Schmidt GA et al.Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children.J Pediatr. 1997; 130: 217-224Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar Thus, there are both theoretical and empiric data to suggest that heliox might be useful. In fact, in our study,5Manthous CA Hall JB Caputo MA et al.The effect of heliox on pulsus paradoxus and peak flows in patients with severe asthma.Am J Respir Crit Care Med. 1995; 151: 310-314Crossref PubMed Scopus (170) Google Scholar heliox was associated with a 30% reduction in pulsus paradoxus, which is thought to reflect the work of breathing in patients with acute asthma. Why does that not translate to an observable difference in outcomes? The reason may be that most patients with acute asthma (ie, more than two thirds) get better without it.7Strauss L Hejal R Galan G et al.Observations on the effects of aerosolized albuterol in acute asthma.Am J Respir Crit Care Med. 1997; 155: 454-458Crossref PubMed Scopus (111) Google Scholar8Rodrigo G Rodrigo C First-line therapy of adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.Am J Respir Crit Care Med. 2000; 161: 1862-1868Crossref PubMed Scopus (137) Google Scholar In my opinion, the correct experiment has not been performed yet. If we hypothesize that heliox reduces the rate of intubation of all patients with acute asthma from 1 to 0.2%, then one needs 654 patients (to demonstrate this fivefold reduction in intubation) at a power of 80%. Even if 5% of all patients are intubated (which is more than the number in most published series), 116 patients are required to demonstrate a fivefold difference at an 80% power. No study has been powered sufficiently to answer the question. It is not the right question anyway. Why use heliox on the two thirds of asthmatic patients who get better after three back-to-back aerosol treatments? What we really need to know is whether heliox can be used to reduce the need for intubation in those patients with the worst exacerbations. Thus, it is premature to conclude that heliox cannot be used to reduce the rate of intubation of patients with severe asthma. Although Kress and colleagues9Kress JP Noth I Gehlbach BK et al.The utility of albuterol nebulized with heliox during acute asthma exacerbations.Am J Respir Crit Care Med. 2002; 165: 1317-1321Crossref PubMed Scopus (90) Google Scholar showed that heliox, when used to carry aerosols to the lungs of patients with acute asthma, improves their expiratory flow rates, no study has demonstrated improved outcomes (eg, disposition, length of stay, and intubation) when heliox is used as the aerosol carrier gas. Finally, one may ask whether there is a role for heliox in mechanically ventilated patients. Studies by Menitove and Goldring10Menitove SM Goldring RM Combined ventilator and bicarbonate strategy in the management of status asthmaticus.Am J Med. 1983; 74: 898-901Abstract Full Text PDF PubMed Scopus (82) Google Scholar and Darioli and Perret11Darioli R Perret C Mechanical controlled hypoventilation in status asthmaticus.Am Rev Respir Dis. 1984; 129: 385-387PubMed Google Scholar have demonstrated that mortality from mechanical ventilation for asthma can be eliminated using techniques to reduce dynamic hyperinflation. No similar data exist for heliox when it is used in such cases. Thus it should not be used in this situation unless permissive hypoventilation has failed to achieve safe airway pressures and/or the patient exhibits the cardiopulmonary effects of dynamic hyperinflation (ie, shock or barotrauma). Since I left my fellowship, where we used heliox in such patients occasionally, I have been successful in treating patients with the most severe cases of asthma using a plateau-pressure-targeted (ie, < 30 cm H2O) hypoventilation strategy. Heliox has never been required. Yet, it is nice to know that it can be “pulled out”1Manthous CA Morgan S Pohlman A et al.Heliox in the treatment of airflow obstruction: a critical review of the literature.Respir Care. 1997; 42: 1034-1042Google Scholar as rescue therapy for “asthma from hell” when everything else is not working. Luckily, I have not encountered such a case in the past 10 years. So to conclude, the review by Rodrigo and Rodrigo notwithstanding, no published study has examined the relevant question: does heliox, when inhaled to reduce the work of breathing or to propel therapeutic aerosols more efficiently, improve the outcomes of patients with refractory airflow obstruction, that is, those who do not get better after initial therapies in the emergency department? Until such studies are performed, the role of heliox to reduce the work of breathing for the purpose of forestalling intubation and to deliver aerosols is not certain. Heliox should not be used in all patients with acute asthma, but it may be effective (if used carefully1Manthous CA Morgan S Pohlman A et al.Heliox in the treatment of airflow obstruction: a critical review of the literature.Respir Care. 1997; 42: 1034-1042Google Scholar) in selected patients with the most severe, refractory status asthmaticus. Until such studies are published, heliox should be used cautiously by experienced personnel, preferably in study circumstances." @default.
• W2011648469 created "2016-06-24" @default.
• W2011648469 creator A5013905161 @default.
• W2011648469 date "2003-03-01" @default.
• W2011648469 modified "2023-10-14" @default.
• W2011648469 title "Heliox for Status Asthmaticus?" @default.
• W2011648469 cites W1569642396 @default.
• W2011648469 cites W1998024345 @default.
• W2011648469 cites W2021472715 @default.
• W2011648469 cites W2026934822 @default.
• W2011648469 cites W2081189862 @default.
• W2011648469 cites W2085766880 @default.
• W2011648469 cites W2091959059 @default.
• W2011648469 cites W2135580928 @default.
• W2011648469 cites W2210252400 @default.
• W2011648469 cites W2301066258 @default.
• W2011648469 cites W2318774643 @default.
• W2011648469 doi "https://doi.org/10.1378/chest.123.3.676" @default.
• W2011648469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12628860" @default.
• W2011648469 hasPublicationYear "2003" @default.
• W2011648469 type Work @default.
• W2011648469 sameAs 2011648469 @default.
• W2011648469 citedByCount "3" @default.
• W2011648469 crossrefType "journal-article" @default.
• W2011648469 hasAuthorship W2011648469A5013905161 @default.
• W2011648469 hasBestOaLocation W20116484691 @default.
• W2011648469 hasConcept C177713679 @default.
• W2011648469 hasConcept C2780467175 @default.
• W2011648469 hasConcept C42219234 @default.
• W2011648469 hasConcept C71924100 @default.
• W2011648469 hasConceptScore W2011648469C177713679 @default.
• W2011648469 hasConceptScore W2011648469C2780467175 @default.
• W2011648469 hasConceptScore W2011648469C42219234 @default.
• W2011648469 hasConceptScore W2011648469C71924100 @default.
• W2011648469 hasIssue "3" @default.
• W2011648469 hasLocation W20116484691 @default.
• W2011648469 hasLocation W20116484692 @default.
• W2011648469 hasOpenAccess W2011648469 @default.
• W2011648469 hasPrimaryLocation W20116484691 @default.
• W2011648469 hasRelatedWork W1981924767 @default.
• W2011648469 hasRelatedWork W2042545598 @default.
• W2011648469 hasRelatedWork W2051609830 @default.
• W2011648469 hasRelatedWork W2064717856 @default.
• W2011648469 hasRelatedWork W2084992476 @default.
• W2011648469 hasRelatedWork W2187505218 @default.
• W2011648469 hasRelatedWork W2337434280 @default.
• W2011648469 hasRelatedWork W2549135832 @default.
• W2011648469 hasRelatedWork W3165497508 @default.
• W2011648469 hasRelatedWork W4252371801 @default.
• W2011648469 hasVolume "123" @default.
• W2011648469 isParatext "false" @default.
• W2011648469 isRetracted "false" @default.
• W2011648469 magId "2011648469" @default.
• W2011648469 workType "article" @default.